By: Marcia Frellick
November 03, 2025 CHICAGO — Positive phase 3 trials for two drugs, telitacicept and ianalumab, showed promise for offering systemic treatment for Sjögren disease, rather than only symptom control.
United States (National)
Marcia Frellick
Geo Focus
Coverage Attributes:
Beta
Cites Data:
32
%
Informative:
29
%
Data Driven:
25
%
Government Announcement:
3
%
Press Release:
2
%
Themes Covered:
Not enough data
Pitching Insights
Marcia Frellick's articles predominantly cover healthcare and scientific topics, with a strong emphasis on citing data. She appears to value evidence-based reporting, making her receptive to pitches that offer new or comprehensive data analysis in the fields of medical research, autoimmune diseases, cancer care, HIV vaccine trials, and other related areas.
Given her focus on expert commentary and substantial reliance on data for her articles, she may be interested in receiving pitches from renowned experts who can provide insights into ongoing medical research or developments within the healthcare field. Pitches offering access to credible sources involved in groundbreaking studies or clinical trials related to the covered topics could also be well-received by Marcia.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Journalist
Publications
Most recent topics
Not enough data
